Trial · NCT07888140
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
NCT07888140, Phase 3, Recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer. Trials, record NCT07888140. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
- NCT number
- NCT07888140
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Esophageal Cancer
- Interventions
- Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Textbook Outcome (TO) Rate | Within 30 days after surgery | The proportion of participants achieving a textbook outcome within 30 days after surgery. Textbook outcome is defined as the composite achievement of all of the following: R0 resection; retrieval of at least 20 lymph nodes; no intraoperative complications; no Clavien-Dindo grade III or higher complications; no ICU/MCU readmission; no surgery-related readmission within 30 days after discharge; no anastomotic leakage of any ECCG grade; length of hospital stay less than 14 days; and no in-hospital death. |
| Secondary | Surgical Preparation Time | During surgery | Time from the initiation of anesthesia to the time when the primary surgeon is able to begin the surgical procedure. |
| Secondary | Operative Time | During surgery | Time from the start of the surgical procedure by the primary surgeon to completion of skin closure. |
| Secondary | Total Operative Time | During surgery | Time from the patient's entry into the operating room to completion of skin closure. |
| Secondary | Intraoperative Blood Loss | During surgery | Total estimated blood loss from the start of surgery to completion of wound closure, measured by visual estimation, suction volume, or weighing of blood-soaked materials. |
| Secondary | Intraoperative Blood Transfusion Rate | During surgery | Proportion of participants who receive a blood transfusion during surgery. |
| Secondary | Postoperative Pain Score | At 24 hours after surgery and before hospital discharge | Pain will be assessed using the modified Wong-Baker Faces Pain Rating Scale. |
| Secondary | Conversion Rate | During surgery | Proportion of participants requiring unplanned conversion of the assigned minimally invasive surgical approach to another surgical approach during the procedure. In the robot-assisted group, conversion to conventional thoracoscopic or open surgery will be recorded; in the conventional minimally invasive surgery group, conversion to open surgery will be recorded. |
| Secondary | Postoperative Length of Hospital Stay | Perioperative | Length of hospital stay following surgery, calculated as the number of days from hospital admission to hospital discharge. |
| Secondary | EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) | Baseline and at 30 days, 3 months, 6 months, 1 year, 2 years, and 3 years after surgery | Quality of life will be assessed using the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30). |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888140
GET https://conductscience.org/api/trials/v1/NCT07888140/registered